• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对于肢端肥大症的诊断,3小时自发性生长激素分泌曲线与口服葡萄糖耐量试验一样可靠。

Three-hour spontaneous GH secretion profile is as reliable as oral glucose tolerance test for the diagnosis of acromegaly.

作者信息

Grottoli S, Razzore P, Gaia D, Gasperi M, Giusti M, Colao A, Ciccarelli E, Gasco V, Martino E, Ghigo E, Camanni F

机构信息

Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Turin, Turin, Italy.

出版信息

J Endocrinol Invest. 2003 Feb;26(2):123-7. doi: 10.1007/BF03345139.

DOI:10.1007/BF03345139
PMID:12739738
Abstract

The diagnosis of acromegaly, in an appropriate clinical context, usually relies on lack of GH suppression below 1 microg/l during OGTT coupled with elevated IGF-I levels. On the other hand, in normal subjects glucose-induced inhibition of GH secretory bursts without any further decrease of interpulse GH levels had already been shown. Based on the foregoing, we aimed to compare the diagnostic reliability of OGTT-induced GH nadir with that recorded during 3-h spontaneous GH secretion. In 59 acromegalic patients (17 male and 42 female, age, mean +/- SE 51.5 +/- 1.9, range 21-76 yr) and in 82 normal subjects (43 male and 39 female, age, mean +/- SE 35.7 +/- 1.5, range 15-72 yr) GH secretion was evaluated every 30 min from 0 to 180 min during slow saline infusion or OGTT (75 g at 0 min). A nadir GH concentration below 1 microg/l was recorded in all normal subjects either during OGTT or saline infusion if GH secretion was evaluated over 180 min. In contrast in acromegalic patients a nadir GH concentration below 1 microg/l never occurred in both conditions. This study shows that a 3-h spontaneous GH profile is as reliable as OGTT in the diagnosis of active acromegaly.

摘要

在适当的临床背景下,肢端肥大症的诊断通常依赖于口服葡萄糖耐量试验(OGTT)期间生长激素(GH)抑制水平未降至1μg/L以下,同时伴有胰岛素样生长因子-I(IGF-I)水平升高。另一方面,在正常受试者中,已证实葡萄糖可抑制GH分泌脉冲,但脉冲间期GH水平无进一步下降。基于上述情况,我们旨在比较OGTT诱导的GH最低点与3小时自发性GH分泌记录的诊断可靠性。对59例肢端肥大症患者(男17例,女42例,年龄平均±标准误51.5±1.9岁,范围21 - 76岁)和82例正常受试者(男43例,女39例,年龄平均±标准误35.7±1.5岁,范围15 - 72岁)在缓慢输注生理盐水或OGTT(0分钟时给予75g葡萄糖)期间,每隔30分钟评估一次GH分泌,持续0至180分钟。如果对GH分泌进行180分钟以上的评估,在所有正常受试者的OGTT或生理盐水输注期间,均记录到GH最低点浓度低于1μg/L。相反,在肢端肥大症患者中,在这两种情况下均未出现GH最低点浓度低于1μg/L的情况。本研究表明,3小时自发性GH谱在诊断活动性肢端肥大症方面与OGTT一样可靠。

相似文献

1
Three-hour spontaneous GH secretion profile is as reliable as oral glucose tolerance test for the diagnosis of acromegaly.对于肢端肥大症的诊断,3小时自发性生长激素分泌曲线与口服葡萄糖耐量试验一样可靠。
J Endocrinol Invest. 2003 Feb;26(2):123-7. doi: 10.1007/BF03345139.
2
Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure?使用灵敏的生长激素检测法评估经治疗的肢端肥大症患者的疾病活动度:生化治愈是否应达到严格的正常生长激素水平?
J Clin Endocrinol Metab. 2002 Jul;87(7):3142-7. doi: 10.1210/jcem.87.7.8631.
3
Hormonal diagnosis of GH hypersecretory states.生长激素分泌过多状态的激素诊断。
J Endocrinol Invest. 2003;26(10 Suppl):27-35.
4
Discordant nadir GH after oral glucose and IGF-I levels on treated acromegaly: refining the biochemical markers of mild disease activity.口服葡萄糖后 GH 水平和 IGF-I 水平不一致,且肢端肥大症患者经治疗后 GH 水平降低:轻度疾病活动的生化标志物的精细化。
Horm Metab Res. 2010 Jan;42(1):50-5. doi: 10.1055/s-0029-1239522. Epub 2009 Oct 1.
5
Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly.年龄会改变肢端肥大症术后患者口服葡萄糖后平均生长激素水平和生长激素最低点水平的诊断准确性。
Clin Endocrinol (Oxf). 2006 Aug;65(2):250-6. doi: 10.1111/j.1365-2265.2006.02584.x.
6
Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly.采用生长激素分泌敏感指标对60例肢端肥大症术后患者的疾病状态进行评估。
J Clin Endocrinol Metab. 1998 Nov;83(11):3808-16. doi: 10.1210/jcem.83.11.5266.
7
Ghrelin test for the assessment of GH status in successfully treated patients with acromegaly.用于评估经成功治疗的肢端肥大症患者生长激素(GH)状态的胃饥饿素检测
Eur J Endocrinol. 2006 May;154(5):659-66. doi: 10.1530/eje.1.02148.
8
Is GH nadir during OGTT a reliable test for diagnosis of acromegaly in patients with abnormal glucose metabolism?OGTT 时 GH 谷值是否可作为葡萄糖代谢异常患者中诊断肢端肥大症的可靠试验?
Endocrine. 2019 Apr;64(1):139-146. doi: 10.1007/s12020-018-1805-z. Epub 2018 Nov 10.
9
The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy.经成功治疗的肢端肥大症患者24小时生长激素分泌与胰岛素样生长因子I之间的关系:手术或放疗的影响
J Clin Endocrinol Metab. 2001 Jan;86(1):259-66. doi: 10.1210/jcem.86.1.7154.
10
Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up.生长激素分泌看似正常的肢端肥大症:对诊断和随访的意义
J Clin Endocrinol Metab. 2002 Aug;87(8):3537-42. doi: 10.1210/jcem.87.8.8658.

引用本文的文献

1
In Search of the Hyperglycemic Threshold Required to Induce Growth Hormone (GH) Suppression.寻找诱导生长激素(GH)抑制所需的高血糖阈值。
Cureus. 2023 Jan 31;15(1):e34463. doi: 10.7759/cureus.34463. eCollection 2023 Jan.
2
[The role of glucose and insulin in the metabolic regulation of growth hormone secretion].[葡萄糖和胰岛素在生长激素分泌的代谢调节中的作用]
Probl Endokrinol (Mosk). 2021 Jan 21;67(1):52-59. doi: 10.14341/probl12660.
3
Acromegaly in the elderly patients.老年患者的肢端肥大症。

本文引用的文献

1
Criteria for cure of acromegaly: a consensus statement.肢端肥大症治愈标准:一项共识声明。
J Clin Endocrinol Metab. 2000 Feb;85(2):526-9. doi: 10.1210/jcem.85.2.6363.
2
Determinants of circulating insulin-like growth factor-I.
J Endocrinol Invest. 1999;22(5 Suppl):48-57.
3
Investigation protocol: acromegaly and its investigation.调查方案:肢端肥大症及其调查
Clin Endocrinol (Oxf). 1999 Mar;50(3):285-93. doi: 10.1046/j.1365-2265.1999.00615.x.
Endocrine. 2020 Apr;68(1):16-31. doi: 10.1007/s12020-020-02206-7. Epub 2020 Feb 14.
4
Biochemical investigations in diagnosis and follow up of acromegaly.肢端肥大症诊断与随访中的生化检查
Pituitary. 2017 Feb;20(1):33-45. doi: 10.1007/s11102-017-0792-z.
5
Safety and specificity of the growth hormone suppression test in patients with diabetes.糖尿病患者生长激素抑制试验的安全性和特异性
Endocrine. 2015 Feb;48(1):329-33. doi: 10.1007/s12020-014-0282-2. Epub 2014 May 17.
6
Biochemical diagnosis and assessment of disease activity in acromegaly: a two-decade experience.肢端肥大症的生化诊断和疾病活动评估:二十年经验。
Pituitary. 2012 Jun;15(2):215-21. doi: 10.1007/s11102-011-0313-4.
7
Adrenal lesions in acromegaly: do metabolic aspects and aryl hydrocarbon receptor interacting protein gene have a role? Evaluation at baseline and after long-term follow-up.肢端肥大症中的肾上腺病变:代谢方面和芳烃受体相互作用蛋白基因是否起作用?在基线和长期随访后的评估。
J Endocrinol Invest. 2011 May;34(5):353-60. doi: 10.1007/BF03347459. Epub 2010 Jul 1.
8
The R304X mutation of the aryl hydrocarbon receptor interacting protein gene in familial isolated pituitary adenomas: Mutational hot-spot or founder effect?家族性孤立性垂体腺瘤中芳香烃受体相互作用蛋白基因的 R304X 突变:突变热点还是起源效应?
J Endocrinol Invest. 2010 Dec;33(11):800-5. doi: 10.1007/BF03350345. Epub 2010 Mar 30.
9
Clinical aspects and therapeutic outcome in thyrotropin-secreting pituitary adenomas: a single center experience.促甲状腺激素分泌垂体腺瘤的临床特点和治疗效果:单中心经验。
J Endocrinol Invest. 2009 Oct;32(9):773-9. doi: 10.1007/BF03346535.
10
Dynamic tests for the diagnosis and assessment of treatment efficacy in acromegaly.用于肢端肥大症诊断和治疗疗效评估的动态测试。
Pituitary. 2008;11(2):129-39. doi: 10.1007/s11102-008-0113-7.
4
Evaluation of disease activity by IGF-I and IGF binding protein-3 (IGFBP3) in acromegaly patients distributed according to a clinical score.根据临床评分对肢端肥大症患者,通过胰岛素样生长因子-I(IGF-I)和胰岛素样生长因子结合蛋白-3(IGFBP3)评估疾病活动度。
J Endocrinol Invest. 1999 Jan;22(1):29-34. doi: 10.1007/BF03345475.
5
Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly.采用生长激素分泌敏感指标对60例肢端肥大症术后患者的疾病状态进行评估。
J Clin Endocrinol Metab. 1998 Nov;83(11):3808-16. doi: 10.1210/jcem.83.11.5266.
6
Growth-hormone and prolactin excess.生长激素和催乳素分泌过多。
Lancet. 1998 Oct 31;352(9138):1455-61. doi: 10.1016/S0140-6736(98)03356-X.
7
Current treatment guidelines for acromegaly.肢端肥大症的现行治疗指南。
J Clin Endocrinol Metab. 1998 Aug;83(8):2646-52. doi: 10.1210/jcem.83.8.4995.
8
Growth hormone, insulin-like growth factor-I and its binding proteins in the follow-up of acromegaly.
J Endocrinol. 1997 Oct;155 Suppl 1:S17-9; discussion S21.
9
A comparison of different methods for diagnosing acromegaly.肢端肥大症不同诊断方法的比较。
Clin Endocrinol (Oxf). 1997 May;46(5):531-7. doi: 10.1046/j.1365-2265.1997.1430983.x.
10
Somatotrope responsiveness to Hexarelin, a synthetic hexapeptide, is refractory to the inhibitory effect of glucose in obesity.生长激素细胞对合成六肽Hexarelin的反应性在肥胖状态下对葡萄糖的抑制作用具有抗性。
Eur J Endocrinol. 1996 Dec;135(6):678-82. doi: 10.1530/eje.0.1350678.